Edition:
United States

Repros Therapeutics Inc (RPRX.OQ)

RPRX.OQ on NASDAQ Stock Exchange Capital Market

1.16USD
24 Mar 2017
Change (% chg)

$-0.03 (-2.52%)
Prev Close
$1.19
Open
$1.15
Day's High
$1.21
Day's Low
$1.15
Volume
13,622
Avg. Vol
24,080
52-wk High
$3.48
52-wk Low
$0.81

Latest Key Developments (Source: Significant Developments)

Repros announces new CEO
Thursday, 2 Feb 2017 09:15am EST 

Repros Therapeutics Inc : Repros announces new CEO . Says ceo and president Joseph S. Podolski resigned .Larry Dillaha was appointed interim president and chief executive officer of company, effective immediately.  Full Article

FDA Advisory Committee discusses clinical trial designs for obesity-related hypogonadism
Tuesday, 6 Dec 2016 08:01pm EST 

Repros Therapeutics Inc : Says intends to meet with FDA to discuss design of a definitive phase 3 study that incorporates advice of committee .FDA Advisory Committee discusses clinical trial designs for obesity-related hypogonadism.  Full Article

Repros says groups showed improvement in Enclomiphene study
Monday, 15 Aug 2016 04:01pm EDT 

Repros Therapeutics Inc : Repros provides six month interim results for Enclomiphene study in obese secondary Hypogonadal men .All groups showed statistically significant improvement in all metabolic parameters tested..  Full Article

Repros Therapeutics - entered into a sales agreement with Ladenburg Thalmann & Co under which co may offer its shares of up to $10 million
Tuesday, 9 Aug 2016 04:25pm EDT 

Repros Therapeutics Inc :Entered into a sales agreement with Ladenburg Thalmann & Co under which co may offer its shares of up to $10 million.  Full Article

Repros Therapeutics Inc. reported Q2 EPS ($0.18)
Tuesday, 9 Aug 2016 09:15am EDT 

Repros Therapeutics Inc : Repros Therapeutics Inc. reports second quarter 2016 financial results .Q2 loss per share $0.18.  Full Article

Repros Therapeutics reports Q1 loss per share of $0.20
Tuesday, 10 May 2016 09:15am EDT 

Repros Therapeutics Inc : Repros therapeutics inc.® reports first quarter 2016 financial results .Q1 loss per share $0.20.  Full Article

More From Around the Web

BRIEF-Repros announces new CEO

* Larry Dillaha was appointed interim president and chief executive officer of company, effective immediately Source text for Eikon: Further company coverage: